Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake

Clinical Endocrinology

Volumn 68, Issue 1, 2008, Pages 108-116

  Mian, Caterina ^a,b   Barollo, Susi ^a   Pennelli, Gianmaria ^a   Pavan, Nicodemo ^a   Rugge, Massimo ^a   Pelizzo, Maria Rosa ^a   Mazzarotto, Renzo ^a   Casara, Dario ^a   Nacamulli, Davide ^a   Mantero, Franco ^a   Opocher, Giuseppe ^a   Busnardo, Benedetto ^a   Girelli, Maria Elisa ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Institute of Semeiotica Medica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE ISOENZYME; IODINE 131; MESSENGER RNA; PENDRIN; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID PEROXIDASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER TISSUE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN TISSUE; MALE; METABOLIC REGULATION; METASTASIS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; RADIOISOTOPE THERAPY; THYROID PAPILLARY CARCINOMA;

ADULT; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYMPORTERS; THYROGLOBULIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 36949011598     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03008.x     Document Type: Article

References (35)

1. Dai, G., Levy, O. Carrasco, N. (1996) Cloning and characterization of the thyroid iodide transporter. Nature, 379, 458 460.
2. - symporter: mechanism, stoichiometry, and specificity. Journal of Biological Chemistry, 272, 27230 27238.
3. Royaux, I.E., Suzuki, K., Mori, A., Katoh, R., Everett, L.A., Kohon, L.D. Green, E.D. (2000) Pendrin, the protein encoded by the Pendred's syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. Endocrinology, 141, 839 845.
4. Bidart, J.M., Mian, C., Lazar, V., Mahe, C., Filetti, S., Caillou, B. Schlumberger, M. (2000) Expression of pendrin and Pendred syndrome (PDS) gene in human thyroid tissues. Journal of Clinical Endocrinology and Metabolism, 85, 2028 2033.
5. Mazzaferri, E.L. (1996) Carcinoma of follicular epithelium: radioiodine and other treatment outcomes. In : L. E. Braverman, R. D. Utiger eds. The Thyroid - A Fundamental and Clinical Text, 7th edn. Lippincott-Raven, Philadelphia, 922 945.
6. Schlumberger, M. Baudin, E. (1998) Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. European Journal of Endocrinology, 138, 249 252.
7. Schlumberger, M. (1998) Papillary and follicular thyroid carcinoma. New England Journal of Medicine, 338, 297 306.
8. Helal, B.O., Merlet, P., Toubert, M.E., Franc, B., Schvartz, C. Gauthier-Koelesnikov, H. (2001) Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. Journal of Nuclear Medicine, 42, 1464 1469.
9. Schonberger, J., Rushoff, J., Grimm, D., Marienhagen, J., Rummele, P., Meyringer, R., Kossmehl, P., Hofstaedter, F. Eilles, C. (2002) Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavourable prognosis: an immunohistochemical study. Thyroid, 12, 747 754.
10. WHO, UNICEF, ICCIDD (1994) Indicators for Assessing Iodine Deficiency Disorders and Their Control through Salt Iodization. World Health Organization, Geneva, Switzerland.
11. American Joint Committee on Cancer (2002) AJCC Cancer Staging Manual, 6th edn. Wiley-Liss, New York.
12. van Diest, P.J. (2002) No consent should be needed for using leftover body material for scientific purposes. British Medical Journal, 325, 648 651.
13. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism, 84, 3228 3234.
14. Mian, C., Lacroix, L., Alzieu, L., Nocera, M., Bidart, J.M., Lazar, V., Talbot, M., Schmumberger, M. Caillou, B. (2001) NIS and Pendrin expressions in human thyroid tissues. Thyroid, 11, 825 830.
15. Trouttet-Masson, S., Selmi-Ruby, S., Bernier-Valentin, F., Porra, V., Berger-Dutrieux, N., Decaussin, M., Peix, J.L., Perrin, A., Bournaud, C., Orgiazzi, J., Borson-Chazot, F., Franc, B. Rousset, B. (2004) Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. American Journal of Pathology, 165, 25 34.
16. Park, H.J., Kim, J.Y., Park, K.Y., Gong, G., Hong, S.J. Ahn, I.M. (2000) Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid, 10, 211 217.
17. Arturi, F., Russo, D., Giuffrida, D., Schlumberger, M. Filetti, S. (2000) Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. European Journal of Endocrinology, 143, 623 627.
18. Tonacchera, M., Viacava, P., Agretti, P., de Marco, G., Perri, A., di Cosmo, C., de Servi, M., Miccoli, P., Lippi, F., Naccarato, A.G., Pinchera, A., Chiovato, L. Vitti, P. (2002) Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. Journal of Clinical Endocrinology and Metabolism, 87, 352 357.
19. Wapnir, I.L., van de Rijn, M., Nowels, K., Amenta, P.S., Walton, K., Montgomery, K., Greco, R.S., Dohan, O. Carrasco, N. (2003) Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. Journal of Clinical Endocrinology and Metabolism, 88, 1880 1888.
20. Gerard, A.C., Daumerie, C., Mestdagh, C., Gohy, S., De Burbure, C., Costagliola, S., Miot, F., Nollevaux, M.C., Denef, J.F., Rahier, J., Franc, B., De Vijlder, J.J., Colin, I.M. Many, M.C. (2003) Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 88, 4977 4983.
21. Boland, A., Magnon, C., Filetti, S., Bidart, J.M., Schlumberger, M., Yeh, P. Perricaudet, M. (2002) Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid, 12, 19 26.
22. Huang, M., Batra, R.K., Kogai, T., Lin, Y.Q., Hershman, J.M., Lichtenstein, A., Sharma, S., Zhu, L.X., Brent, G.A. Dubinett, S.M. (2001) Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Therapy, 8, 612 618.
23. Hung, M.C., Wu, H.S., Kao, C.H., Chen, W.K. Changlai, S.P. (2003) F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocrine Research, 29, 169 175.
24. Kraeber-Bodere, F., Cariou, B., Curtet, C., Bridji, B., Rousseau, C., Dravet, F., Charbonnel, B., Carnaille, B., Le Neel, J.C. Mirallie, E. (2005) Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. Surgery, 138, 1176 1182.
25. Matsuzu, K., Segade, F., Wong, M., Clark, O.H., Perrier, N.D. Bowden, D.W. (2005) Glucose transporters in the thyroid. Thyroid, 15, 545 550.
26. 18F)-fluoro-2-deoxy-D- glucose positron emission tomography scanning. Journal of Clinical Endocrinology and Metabolism, 91, 498 505.
27. Foti, D., Damante, G., Russo, D., Distefano, M., Grasso, G., Fusco, A. Filetti, S. (1993) Molecular mechanisms of increased glucose transport in transformed FRTL-5 rat thyroid cells. Biochemical and Biophysical Research and Communications, 919, 289 294.
28. Chin, B.B., Patel, P., Cohade, C., Ewertz, M., Wahl, R. Ladenson, P. (2004) Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 89, 91 95.
29. Xing, M. (2005) BRAF mutation in thyroid cancer. Endocrine-Related Cancer, 12, 245 262.
30. Nikiforova, M.N., Kimura, E.T., Gandhi, M., Biddinger, P.W., Knauf, J.A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., Santoro, M., Fagin, J.A. Nikiforov, Y. (2003) BRAF mutation in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism, 88, 5399 5404.
31. Xing, M., Westra, W.H., Tufano, R.P., Cohen, Y., Rosenbaum, E., Rhoden, K.J., Carson, K.A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E.H., Hui, P., Umbricht, C.B., Basaria, S., Ewertz, M., Tufaro, A.P., Califano, J.A., Ringel, M.D., Zeiger, M.A., Sidransky, D. Ladenson, P.W. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 90, 6373 6379.
32. Salvatore, G., De Falco, V., Salerno, P., Nappi, T.C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R.M., Wilhelm, S.M. Santoro, M. (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical Cancer Research, 12, 1623 1629.
33. Porra, V., Ferraro-Peyret, C., Durand, C., Selmi-Ruby, S., Giroud, H., Berger-Dutrieux, N., Decaussin, M., Peix, J.L., Bournaud, C., Orgiazzi, J., Borson-Chazot, F., Dante, R. Rousset, B. (2005) Silencing of tumour suppressor gene SLC5A8 is associated with BRAF mutation in classical papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 90, 3028 3035.
34. Giordano. T.J., Kuick, R., Thomas, D.G., Misek, D.E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., Gauger, P., Doherty, G., Thompson, N.W., Hanash, S., Koening, R.J. Nikiforov, Y.E. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarrays analysis. Oncogene, 24, 6646 6656.
35. - targeting to the membrane. Endocrine-Related Cancer, 13, 257 269.